Therapeutic Asset Ratings

223 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Benadryl Lung Cancer	Ciusss de L'Est de l'Île de Montréal	P3	B (56)
Cytosin-Arabinosid Lung Cancer	Pfizer	P3	B (56)
Daunorubicin Lung Cancer	Pfizer	P3	B (56)
Memantine Hydrochloride Lung Cancer	NRG Oncology	P3	B (56)
Bms-907351 Lung Cancer	Jun Zhang, MD, PhD	P2	CCC (55)
Capecitabine Lung Cancer	Odense University Hospital	P2	CCC (55)
Indocyanine Green Lung Cancer	M.D. Anderson Cancer Center	P2	CCC (55)
Vesanoid Lung Cancer	Peking University People's Hospital	P2	CCC (55)
Zimberelimab Lung Cancer	Gilead Sciences	P2	CCC (55)
FULVESTRANT Lung Cancer	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P2	CCC (54)
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP Lung Cancer	EMD Serono Research & Development Institute, Inc.	P3	CCC (53)
Binimetinib Lung Cancer	N.N. Petrov National Medical Research Center of Oncology	P2	CCC (53)
Talzenna Lung Cancer	University Health Network, Toronto	P2	CCC (53)
Bl-M14D1 Lung Cancer	SystImmune Inc.	P3	CCC (52)
Calaspargase Pegol Lung Cancer	Pfizer	P3	CCC (52)
hd204 Lung Cancer	Prestige Biopharma Limited	P3	CCC (52)
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa Lung Cancer	Merck Sharp & Dohme LLC	P3	CCC (52)
Iparomlimab Lung Cancer	Qilu Pharmaceutical Co., Ltd.	P3	CCC (52)
Para-Toluenesulfonamide Lung Cancer	Zhou Chengzhi	P3	CCC (52)
PEGASPARGASE Lung Cancer	Pfizer	P3	CCC (52)
Penpulimab Lung Cancer	Degan Lu	P3	CCC (52)
pf-08634404 Lung Cancer	Pfizer	P3	CCC (52)
Zipalertinib Lung Cancer	Taiho Oncology, Inc.	P3	CCC (52)
[68ga]cbp8 Lung Cancer	Massachusetts General Hospital	P2	CCC (52)
Abemaciclib Lung Cancer	Tango Therapeutics, Inc.	P2	CCC (52)

Showing 51 to 75 of 223 assets

PreviousPage 3 of 9Next